The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-receives-orphan-drug-designation-motixafortide-bl-8040

In the latest Phase 2a trial of the pancreatic cancer treatment from Israel’s BioLineRx (see here) three-quarters of the patients at disease stage 4 were able to get their disease under control. The trial combined BL-8040, KEYTRUDA (Pembrolizumab) and chemotherapy. … Continue reading →

Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors. https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html

Israel’s BiolineRX is to perform a Phase II clinical test combining BiolineRX’s BL-8040 with Merck’s KEYTRUDA anti-PD-1 therapy in the treatment of patients with metastatic pancreatic adenocarcinoma. http://www.globes.co.il/en/article-biolinerx-merck-to-collaborate-on-pancreatic-cancer-treatment-1001094833